Abstract
Endotoxins or lipopolysaccharides (LPS), major components of the cell wall of Gram-negative bacteria, once released from the bacterial outer membrane bind to specific receptors and, in particular, to a membrane-bound receptor, the CD14 (mCD14) and the toll-like receptor 4 present on monocytes / macrophages. In turn, LPS-activated monocytes / macrophages release in the host tissue an array of so-called proinflammatory cytokines and, among them, Tumor Necrosis Factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8 and IL-12 are the major mediators. Before therapy (To) and at the end of 6-month interferon (IFN)-α / Ribavirin (RIB) treatment (T6), circulating endotoxin levels were measured in responder and non responder HCV+ patients. At T0, 57% of the non responders were endotoxin-positive and had, on average, 54 pg / ml of plasma LPS while in 50% of the responder patients endotoxin were found with an average of 29 pg / ml. At T6, in responders LPS were no longer detectable, while in 42% of the non responders LPS were found (average levels 45 pg / ml). In terms of serum cytokine concentration, at T6 IFN-γ levels when compared to those detected at T0 were increased in both endotoxin-positive and endotoxin-negative patients. However, at T6 IL-10 concentration was significantly increased only in the group of endotoxin-negative subjects (responder patients), in comparison to T0 values. The origin of endotoxemia in HCV+ patients seems to be multifactorial, likely depending on impaired phagocytic functions and reduced T-cell mediated antibacterial activity . In these patients, however, one cannot exclude the passage of LPS from the gut flora to the blood stream, owing a condition of altered intestinal permeability. At the same time, a less efficient detoxification of enteric bacterial antigens at the hepatic level should be taken into consideration. Finally, novel therapeutic attempts aimed to neutralize LPS in the host are discussed.
Keywords: endotoxemia lps, impaired phagocytic function, enteric bacterial antigen, novel therapeutic attempt, lactoferrin antibodies
Current Pharmaceutical Design
Title: Biological and Clinical Significance of Endotoxemia in the Course of Hepatitis C Virus Infection
Volume: 8 Issue: 11
Author(s): L. Caradonna, M. L. Mastronardi, T. Magrone, R. Cozzolongo, R. Cuppone, O. G. Manghisi, D. Caccavo, N. M. Pellegrino, A. Amoroso, E. Jirillo and L. Amati
Affiliation:
Keywords: endotoxemia lps, impaired phagocytic function, enteric bacterial antigen, novel therapeutic attempt, lactoferrin antibodies
Abstract: Endotoxins or lipopolysaccharides (LPS), major components of the cell wall of Gram-negative bacteria, once released from the bacterial outer membrane bind to specific receptors and, in particular, to a membrane-bound receptor, the CD14 (mCD14) and the toll-like receptor 4 present on monocytes / macrophages. In turn, LPS-activated monocytes / macrophages release in the host tissue an array of so-called proinflammatory cytokines and, among them, Tumor Necrosis Factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8 and IL-12 are the major mediators. Before therapy (To) and at the end of 6-month interferon (IFN)-α / Ribavirin (RIB) treatment (T6), circulating endotoxin levels were measured in responder and non responder HCV+ patients. At T0, 57% of the non responders were endotoxin-positive and had, on average, 54 pg / ml of plasma LPS while in 50% of the responder patients endotoxin were found with an average of 29 pg / ml. At T6, in responders LPS were no longer detectable, while in 42% of the non responders LPS were found (average levels 45 pg / ml). In terms of serum cytokine concentration, at T6 IFN-γ levels when compared to those detected at T0 were increased in both endotoxin-positive and endotoxin-negative patients. However, at T6 IL-10 concentration was significantly increased only in the group of endotoxin-negative subjects (responder patients), in comparison to T0 values. The origin of endotoxemia in HCV+ patients seems to be multifactorial, likely depending on impaired phagocytic functions and reduced T-cell mediated antibacterial activity . In these patients, however, one cannot exclude the passage of LPS from the gut flora to the blood stream, owing a condition of altered intestinal permeability. At the same time, a less efficient detoxification of enteric bacterial antigens at the hepatic level should be taken into consideration. Finally, novel therapeutic attempts aimed to neutralize LPS in the host are discussed.
Export Options
About this article
Cite this article as:
Caradonna L., Mastronardi L. M., Magrone T., Cozzolongo R., Cuppone R., Manghisi G. O., Caccavo D., Pellegrino M. N., Amoroso A., Jirillo E. and Amati L., Biological and Clinical Significance of Endotoxemia in the Course of Hepatitis C Virus Infection, Current Pharmaceutical Design 2002; 8 (11) . https://dx.doi.org/10.2174/1381612024606983
DOI https://dx.doi.org/10.2174/1381612024606983 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Associations between Adiponectin Gene Variability, Proinflammatory and Angiogenetic Markers: Implications for Microvascular Disease Development in Type 2 Diabetes Mellitus?
Current Vascular Pharmacology Antiviral Drug Discovery Targeting to Viral Proteases
Current Pharmaceutical Design A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets UCP2 and CFH Gene Variants with Genetic Susceptibility to Schizophrenia in Turkish Population
Endocrine, Metabolic & Immune Disorders - Drug Targets P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design The Arrestin Fold: Variations on a Theme
Current Genomics Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
CNS & Neurological Disorders - Drug Targets Recent Developments of Amidine-like Compounds as Selective NOS Inhibitors
Current Enzyme Inhibition Analytical Methods for Determination of ·NO and ·NO2 and their Applicability in Biological Studies
Current Pharmaceutical Analysis The Effects of Butyric Acid on the Differentiation, Proliferation, Apoptosis, and Autophagy of IPEC-J2 Cells
Current Molecular Medicine 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Immunopathogenesis and Immunogenetic Variants in COVID-19
Current Pharmaceutical Design Editorial [ Progress of ‘Current Alzheimer Research’ and Update on Roles of Lipids, Estrogen,Neurotrophins and Cytokines in Alzheimers Disease ]
Current Alzheimer Research Target Identification Strategies in Chemical Genetics
Combinatorial Chemistry & High Throughput Screening Voluntary Running and Environmental Enrichment Restores Impaired Hippocampal Neurogenesis in a Triple Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Aerodynamics and Deposition Effects of Inhaled Submicron Drug Aerosol in Airway Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design